Certara Inc (CERT)

$14.845

+0.17

(+1.12%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Certara Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 90.45M → 85.57M (in $), with an average decrease of 5.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 4.70M → -48.96M (in $), with an average decrease of 1140.5% per quarter

  • Vs TXG

    In the last 1 year, 10x Genomics Inc has given 23.0% return, outperforming this stock by 29.9%

Performance

  • $14.70
    $15.06
    $14.85
    downward going graph

    1.01%

    Downside

    Day's Volatility :2.39%

    Upside

    1.39%

    downward going graph
  • $11.81
    $24.96
    $14.85
    downward going graph

    20.47%

    Downside

    52 Weeks Volatility :52.68%

    Upside

    40.5%

    downward going graph

Returns

PeriodCertara IncSector (Health Care)Index (Russel 2000)
3 Months
-7.79%
-2.6%
0.0%
6 Months
-31.56%
2.2%
0.0%
1 Year
-6.91%
-4.3%
-3.4%
3 Years
-61.45%
19.1%
-4.7%

Highlights

Market Capitalization
2.4B
Book Value
$6.58
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.22
Wall Street Target Price
17.14
Profit Margin
-9.56%
Operating Margin TTM
-6.78%
Return On Assets TTM
1.17%
Return On Equity TTM
-3.2%
Revenue TTM
353.0M
Revenue Per Share TTM
2.23
Quarterly Revenue Growth YOY
1.0%
Gross Profit TTM
203.1M
EBITDA
82.7M
Diluted Eps TTM
-0.22
Quarterly Earnings Growth YOY
-0.14
EPS Estimate Current Year
0.45
EPS Estimate Next Year
0.48
EPS Estimate Current Quarter
0.11
EPS Estimate Next Quarter
0.11

Analyst Recommendation

Buy
    57%Buy
    42%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Certara Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
11
Hold
6
6
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 15.46%

Current $14.85
Target $17.14

Company Financials

FY18Y/Y Change
Revenue
163.7M
-
Net Income
-33.3M
-
Net Profit Margin
-20.31%
-
FY19Y/Y Change
Revenue
208.5M
↑ 27.36%
Net Income
-8.9M
↓ 73.16%
Net Profit Margin
-4.28%
↑ 16.03%
FY20Y/Y Change
Revenue
243.5M
↑ 16.79%
Net Income
-49.4M
↑ 453.41%
Net Profit Margin
-20.28%
↓ 16.0%
FY21Y/Y Change
Revenue
286.1M
↑ 17.48%
Net Income
-13.3M
↓ 73.14%
Net Profit Margin
-4.64%
↑ 15.64%
FY22Y/Y Change
Revenue
335.6M
↑ 17.32%
Net Income
14.7M
↓ 211.04%
Net Profit Margin
4.39%
↑ 9.03%
Q2 FY22Q/Q Change
Revenue
82.8M
↑ 1.48%
Net Income
-589.0K
↓ 126.65%
Net Profit Margin
-0.71%
↓ 3.42%
Q3 FY22Q/Q Change
Revenue
84.7M
↑ 2.34%
Net Income
3.9M
↓ 768.25%
Net Profit Margin
4.65%
↑ 5.36%
Q4 FY22Q/Q Change
Revenue
86.6M
↑ 2.28%
Net Income
9.2M
↑ 133.08%
Net Profit Margin
10.59%
↑ 5.94%
Q1 FY23Q/Q Change
Revenue
90.3M
↑ 4.23%
Net Income
1.4M
↓ 85.2%
Net Profit Margin
1.5%
↓ 9.09%
Q2 FY23Q/Q Change
Revenue
90.5M
↑ 0.17%
Net Income
4.7M
↑ 246.54%
Net Profit Margin
5.2%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
85.6M
↓ 5.39%
Net Income
-49.0M
↓ 1140.48%
Net Profit Margin
-57.22%
↓ 62.42%
FY18Y/Y Change
Total Assets
1.1B
-
Total Liabilities
558.7M
-
FY19Y/Y Change
Total Assets
1.0B
↓ 1.37%
Total Liabilities
545.0M
↓ 2.45%
FY20Y/Y Change
Total Assets
1.3B
↑ 22.4%
Total Liabilities
447.3M
↓ 17.94%
FY21Y/Y Change
Total Assets
1.5B
↑ 19.09%
Total Liabilities
469.9M
↑ 5.06%
FY22Y/Y Change
Total Assets
1.6B
↑ 4.05%
Total Liabilities
493.3M
↑ 4.98%
Q2 FY22Q/Q Change
Total Assets
1.5B
↓ 0.35%
Total Liabilities
453.4M
↓ 1.15%
Q3 FY22Q/Q Change
Total Assets
1.5B
↑ 0.46%
Total Liabilities
454.3M
↑ 0.2%
Q4 FY22Q/Q Change
Total Assets
1.6B
↑ 4.26%
Total Liabilities
493.3M
↑ 8.58%
Q1 FY23Q/Q Change
Total Assets
1.6B
↓ 0.39%
Total Liabilities
481.7M
↓ 2.34%
Q2 FY23Q/Q Change
Total Assets
1.6B
↑ 0.35%
Total Liabilities
475.0M
↓ 1.38%
Q3 FY23Q/Q Change
Total Assets
1.5B
↓ 2.89%
Total Liabilities
475.1M
↑ 0.01%
FY18Y/Y Change
Operating Cash Flow
11.6M
-
Investing Cash Flow
-73.9M
-
Financing Cash Flow
57.3M
-
FY19Y/Y Change
Operating Cash Flow
38.0M
↑ 228.03%
Investing Cash Flow
-9.5M
↓ 87.12%
Financing Cash Flow
-8.5M
↓ 114.82%
FY20Y/Y Change
Operating Cash Flow
44.8M
↑ 17.84%
Investing Cash Flow
-8.6M
↓ 9.51%
Financing Cash Flow
208.2M
↓ 2552.75%
FY21Y/Y Change
Operating Cash Flow
60.4M
↑ 34.76%
Investing Cash Flow
-269.9M
↑ 3034.25%
Financing Cash Flow
123.4M
↓ 40.74%
FY22Y/Y Change
Operating Cash Flow
92.5M
↑ 53.25%
Investing Cash Flow
-27.8M
↓ 89.69%
Financing Cash Flow
-7.4M
↓ 105.97%
Q2 FY22Q/Q Change
Operating Cash Flow
23.3M
↑ 137.26%
Investing Cash Flow
-3.2M
↓ 62.68%
Financing Cash Flow
-3.5M
↑ 132.3%
Q3 FY22Q/Q Change
Operating Cash Flow
24.0M
↑ 3.17%
Investing Cash Flow
-3.3M
↑ 2.66%
Financing Cash Flow
-1.3M
↓ 61.94%
Q4 FY22Q/Q Change
Operating Cash Flow
35.5M
↑ 47.88%
Investing Cash Flow
-12.6M
↑ 279.03%
Financing Cash Flow
-968.0K
↓ 27.98%
Q1 FY23Q/Q Change
Operating Cash Flow
10.0M
↓ 71.94%
Investing Cash Flow
-2.7M
↓ 78.32%
Financing Cash Flow
-850.0K
↓ 12.19%
Q2 FY23Q/Q Change
Operating Cash Flow
18.1M
↑ 81.36%
Investing Cash Flow
-11.7M
↑ 329.55%
Financing Cash Flow
-6.4M
↑ 655.29%

Technicals Summary

Sell

Neutral

Buy

Certara Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Certara Inc
Certara Inc
21.12%
-31.56%
-6.91%
-61.45%
-61.45%
10x Genomics Inc
10x Genomics Inc
19.47%
-21.02%
23.01%
-72.11%
-19.03%
Veeva Systems Inc.
Veeva Systems Inc.
-8.91%
5.91%
-7.15%
-37.4%
77.25%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
12.62%
-8.75%
17.61%
17.61%
17.61%
Healthequity Inc
Healthequity Inc
-7.46%
21.42%
7.55%
-6.37%
-21.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Certara Inc
Certara Inc
100.92
NA
NA
0.45
-0.03
0.01
0.0
6.58
10x Genomics Inc
10x Genomics Inc
NA
NA
NA
-2.12
-0.29
-0.12
0.0
6.31
Veeva Systems Inc.
Veeva Systems Inc.
53.83
53.83
1.27
4.18
0.15
0.05
0.0
25.85
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
21.77
21.77
NA
3.82
0.15
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
451.07
451.07
1.92
1.33
0.01
0.02
0.0
22.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Certara Inc
Certara Inc
Buy
$2.4B
-61.45%
100.92
-9.56%
10x Genomics Inc
10x Genomics Inc
Buy
$5.1B
-19.03%
NA
-37.79%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$28.7B
77.25%
53.83
24.2%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$33.4B
17.61%
21.77
8.91%
Healthequity Inc
Healthequity Inc
Buy
$5.8B
-21.13%
451.07
1.37%

Institutional Holdings

  • BlackRock Inc

    9.07%

  • Vanguard Group Inc

    7.86%

  • Baillie Gifford & Co Limited.

    5.75%

  • William Blair Investment Management, LLC

    4.47%

  • ClearBridge Advisors, LLC

    2.58%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    2.55%

Company Information

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.

Organization
Certara Inc
Employees
1150
CEO
Dr. William F. Feehery Ph.D.
Industry
Healthcare

Discover More

FAQs